<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03140319</url>
  </required_header>
  <id_info>
    <org_study_id>SCARM-Skin-001</org_study_id>
    <nct_id>NCT03140319</nct_id>
  </id_info>
  <brief_title>Transplantation of Fibroblast for Correction of Nasolabial Folds</brief_title>
  <official_title>Autologous Transplantation of Cultured Fibroblast for Correction of Nasolabial Folds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SCARM Institute, Tabriz, Iran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SCARM Institute, Tabriz, Iran</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluated the safety and efficacy of the Autologous cultured fibroblast for
      correction of Nasolabial folds and inhibition of skin aging
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autologous cultured fibroblast which is obtain from the patient's normal skin is harvested
      and expanded in an in vitro. Biopsies samples are obtained from the behind of the patient's
      ear as a source of fibroblasts, then fibroblast cells isolated and expanded through cell
      culture, and used for the correction of Nasolabial folds, deep wrinkles of the forehead.
      Prior to final packaging, cell viability is assessed to be at least 85%
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 10, 2018</start_date>
  <completion_date type="Anticipated">November 26, 2018</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correction of Nasolabial</measure>
    <time_frame>6 months after transplantation</time_frame>
    <description>Evaluate the correction of skin changes after transplantation of autologous fibroblasts by medical examination</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Nasolabial Folds</condition>
  <condition>Skin Aging</condition>
  <arm_group>
    <arm_group_label>Fibroblast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of Fibroblast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>the patient receive placebo injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fibroblast</intervention_name>
    <description>Transplantation of 20 million cell by three injection</description>
    <arm_group_label>Fibroblast</arm_group_label>
    <other_name>Autologous injection of Fibroblast</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Injection of Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Available and willing to attend all follow-up visits.

          -  Age &gt; 18 years.

          -  Able and willing to give informed consent

        Exclusion Criteria:

          -  Known allergy or sensitivity to any cellular products

          -  The subject has received a soft tissue augmentation to the area to be treated within
             the last 6 months.

          -  Subject is unwilling to forgo any cosmetic augmentation procedures for the duration of
             the study.

          -  The subject has received autologous fat transfer in the last 6 months.

          -  Subject is suffering from facial Kaposi's sarcoma.

          -  The subject has active skin diseases or inflammation on or near the area of injection

          -  positive HIV, hepatitis B virus (HBV), hepatitis C virus (HCV)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peyman Keyhanvar, MD, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Deputy for translational medicine of SCARM institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammad Nouri, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Head of SCARM institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raheleh Farahzadi, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>cardiovascular research center, Tabriz University of Medical Sciences, Tabriz, Iran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Samira Asghari, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>SCARM institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peyman Keyhanvar, MD, Ph.D</last_name>
    <phone>0914 114 6863</phone>
    <email>drkeyhanvar@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stem cell and Regenerative Medicine institute (SCARM)</name>
      <address>
        <city>Tabriz</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peyman Keyhanvar, Ph.D</last_name>
    </contact>
    <investigator>
      <last_name>Neda Keyhanvar, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Weiss RA, Weiss MA, Beasley KL, Munavalli G. Autologous cultured fibroblast injection for facial contour deformities: a prospective, placebo-controlled, Phase III clinical trial. Dermatol Surg. 2007 Mar;33(3):263-8.</citation>
    <PMID>17338681</PMID>
  </results_reference>
  <results_reference>
    <citation>Munavalli GS, Smith S, Maslowski JM, Weiss RA. Successful treatment of depressed, distensible acne scars using autologous fibroblasts: a multi-site, prospective, double blind, placebo-controlled clinical trial. Dermatol Surg. 2013 Aug;39(8):1226-36. doi: 10.1111/dsu.12204. Epub 2013 Apr 8.</citation>
    <PMID>23566237</PMID>
  </results_reference>
  <results_reference>
    <citation>Purdue GF, Hunt JL, Still JM Jr, Law EJ, Herndon DN, Goldfarb IW, Schiller WR, Hansbrough JF, Hickerson WL, Himel HN, Kealey GP, Twomey J, Missavage AE, Solem LD, Davis M, Totoritis M, Gentzkow GD. A multicenter clinical trial of a biosynthetic skin replacement, Dermagraft-TC, compared with cryopreserved human cadaver skin for temporary coverage of excised burn wounds. J Burn Care Rehabil. 1997 Jan-Feb;18(1 Pt 1):52-7.</citation>
    <PMID>9063788</PMID>
  </results_reference>
  <results_reference>
    <citation>Rigotti G, Charles-de-SÃ¡ L, Gontijo-de-Amorim NF, Takiya CM, Amable PR, Borojevic R, Benati D, Bernardi P, Sbarbati A. Expanded Stem Cells, Stromal-Vascular Fraction, and Platelet-Rich Plasma Enriched Fat: Comparing Results of Different Facial Rejuvenation Approaches in a Clinical Trial. Aesthet Surg J. 2016 Mar;36(3):261-70. doi: 10.1093/asj/sjv231.</citation>
    <PMID>26879294</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2017</study_first_submitted>
  <study_first_submitted_qc>May 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2017</study_first_posted>
  <last_update_submitted>January 3, 2018</last_update_submitted>
  <last_update_submitted_qc>January 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fibroblast</keyword>
  <keyword>Cell transplantation</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

